Close
Achema middle east
swop processing & packaging

EMA approves Genzyme Framingham manufacturing plant

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Technology Transfer Models for Emerging Pharmaceutical Hubs

Technology Transfer Models for Emerging Pharmaceutical Regions The global pharmaceutical...

Cell and Gene Therapy CMC Trends in Biopharma Manufacturing

Cell and Gene Therapy CMC Trends in Upstream, Downstream,...

The European Medicines Agency (EMA) has approved Genzyme’s manufacturing plant in Framingham, Massachusetts, US for the production of Fabrazyme (agalsidase beta).

Fabrazyme (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.

According to Genzyme, the complete return to normal supply levels of Fabrazyme globally will not be immediate due to production lead times and pending regulatory approvals.

Genzyme president and CEO David Meeker said the approval by the EMA represents an important milestone in their manufacturing recovery and path toward unconstrained supply for all patients.

“Providing the Fabry community with consistent access to treatment, increasing our inventory of Fabrazyme and working toward all regulatory approvals of our Framingham plant are our highest priorities,” Meeker added.

Latest stories

Related stories

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Technology Transfer Models for Emerging Pharmaceutical Hubs

Technology Transfer Models for Emerging Pharmaceutical Regions The global pharmaceutical...

Cell and Gene Therapy CMC Trends in Biopharma Manufacturing

Cell and Gene Therapy CMC Trends in Upstream, Downstream,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »